NICE approve Almirall's Ilumetri

NICE approve Almirall’s Ilumetri, UCB’s Cimzia


The National Institute for Health and Care Excellence (NICE) has recommended Almirall’s Ilumetri and UCB’s Cimzia as treatment options for severe plaque psoriasis in final draft guidelines.

Initially NICE rejected Illumetri for not being cost-effective, but a new negotiated price submitted by the company means that it can now be offered as an alternative for patients who are unable to take systemic non-biological treatments.

Read the full article written by Anna Smith here.

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.